spot_img
Friday, August 12, 2022
More
    HomeHealthStudies of Gilead blood cancer drug interrupted by safety issues

    Studies of Gilead blood cancer drug interrupted by safety issues

    -



    The growth of a blood most cancers drug acquired by Gilead Sciences — the centerpiece of a $5 billion deal — has been interrupted by a doubtlessly critical security problem.

    On Tuesday, the Meals and Drug Administration positioned a partial scientific maintain on 5 scientific trials investigating the mix of the Gilead drug, known as magrolimab, with one other generally used blood most cancers medication. The company stepped in due to an “obvious imbalance in investigator-reported suspected surprising critical antagonistic reactions” between examine arms in a number of of the trials, Gilead mentioned in a press release.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,433FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts